Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier
WebMD

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine
WebMD

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion
    WebMD

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community
    WebMD

    Community

    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Heart Failure Health Center

Font Size
A
A
A

Drug 'New Hope' Against Heart Failure: Expert

Experimental medication beat standard treatment at reducing hospitalizations, cardiovascular deaths

WebMD News from HealthDay

By Steven Reinberg

HealthDay Reporter

SATURDAY, Aug. 30, 2014 (HealthDay News) -- In a head-to-head comparison, an experimental drug was more effective than standard treatment at preventing deaths and hospitalizations in heart failure patients.

According to the study authors, the trial was stopped early because of the marked benefit of the new drug, dubbed LCZ696.

In the trial, 26.5 percent of those getting the standard medication, enalapril (Vasotec), either died or were hospitalized due to heart failure, compared with 21.8 percent of those on the new drug. Enalapril belongs to a class of blood pressure-lowering medications known as ACE inhibitors.

"LCZ696 could become the new gold standard, replacing ACE inhibitors," said lead researcher Dr. John McMurray, a professor of cardiology at the British Heart Foundation Cardiovascular Research Center at the University of Glasgow, in Scotland.

LCZ696 combines two blood pressure drugs -- an angiotensin II receptor blocker (ARB) and the neprilysin inhibitor known as sacubitril.

"We found that LCZ696 was superior to the gold-standard ACE inhibitor for heart failure -- an ACE inhibitor being the absolute cornerstone of treatment for this problem," he said.

Not only did LCZ696 beat enalapril, but it did that even when added to other treatments, McMurray noted.

"The new treatment was very well tolerated, with no significant safety concerns," he added.

The report was published online Aug. 30 in the New England Journal of Medicine, to coincide with a presentation at the European Society of Cardiology annual meeting in Barcelona. The trial was funded by Novartis, the maker of LCZ696.

Dr. Mariell Jessup, a professor of medicine at the University of Pennsylvania's Perelman School of Medicine, said, "There is new hope for heart failure."

She added, "We have not had a new drug for heart failure for many years. LCZ696 is a unique compound that may represent a new approach."

Doctors have relied on ACE inhibitors for over two decades, she said. According to Jessup, who wrote an accompanying editorial, "Newer drugs that work via alternate pathways may [show] benefit beyond the medical therapy that is used today."

Today on WebMD

Compressed heart
Article
Salt Shockers
Slideshow
 
Inside A Heart Attack
Slideshow
lowering blood pressure
SLIDESHOW
 

Mechanical Heart
Article
Omega 3 Overview Slideshow
Slideshow
 
Atrial Fibrillation Guide
Slideshow
Simple Steps to Lower Cholesterol
Slideshow
 

Compressed heart
Article
FAQ Heart Failure
Article
 
Cholesterol Confusion
Health Check
Resolved To Quit Smoking
Slideshow
 

WebMD Special Sections